Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases
- 1 April 2001
- journal article
- Published by Elsevier in The American Journal of Medicine
- Vol. 110 (6) , 438-441
- https://doi.org/10.1016/s0002-9343(01)00642-8
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- Continuing nephrological education. Iatrogenic hyperkalaemia-points to consider in diagnosis and managementNephrology Dialysis Transplantation, 1998
- Effectiveness of Spironolactone Added to an Angiotensin-Converting Enzyme Inhibitor and a Loop Diuretic for Severe Chronic Congestive Heart Failure (The Randomized Aldactone Evaluation Study [RALES])**See Appendix for full list of RALES investigators.The American Journal of Cardiology, 1996
- Hyperkalaemia in diabetes: prevalence and associationsPublished by Oxford University Press (OUP) ,1995
- Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitorThe American Journal of Cardiology, 1993
- Captopril and spironolactone therapy for refractory congestive heart failureThe American Journal of Cardiology, 1993
- Angiotensin-converting enzyme inhibitors and renal function in heart failureThe American Journal of Cardiology, 1992
- Effects of Enalapril on Mortality in Severe Congestive Heart FailureNew England Journal of Medicine, 1987
- Incidence of hyperkalaemia induced by indomethacin in a hospital population.BMJ, 1985
- Hyperkalaemia in diabetes mellitus—potential hazards of coexisting hyporeninaemic hypoaldosteronismPublished by Oxford University Press (OUP) ,1984